Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Abstract | BACKGROUND & AIMS: METHODS: In a study performed at 30 Dutch hospitals, patients were assigned randomly to groups that received standard treatment (control) or pretreatment screening (intervention) for 3 common variants of TPMT (TPMT*2, TPMT*3A, and TPMT*3C). Patients in the intervention group found to be heterozygous carriers of a variant received 50% of the standard dose of thiopurine ( azathioprine or 6-mercaptopurine), and patients homozygous for a variant received 0%-10% of the standard dose. We compared, in an intention-to-treat analysis, outcomes of the intervention (n = 405) and control groups (n = 378) after 20 weeks of treatment. Primary outcomes were the occurrence of hematologic ADRs (leukocyte count < 3.0*10(9)/L or reduced platelet count < 100*10(9)/L) and disease activity (based on the Harvey-Bradshaw Index for Crohn's disease [n = 356] or the partial Mayo score for ulcerative colitis [n = 253]). RESULTS: Similar proportions of patients in the intervention and control groups developed a hematologic ADR (7.4% vs 7.9%; relative risk, 0.93; 95% confidence interval, 0.57-1.52) in the 20 weeks of follow-up evaluation; the groups also had similar mean levels of disease activity (P = .18 for Crohn's disease and P = .14 for ulcerative colitis). However, a significantly smaller proportion of carriers of the TPMT variants in the intervention group (2.6%) developed hematologic ADRs compared with patients in the control group (22.9%) (relative risk, 0.11; 95% confidence interval, 0.01-0.85). CONCLUSIONS: Screening for variants in TPMT did not reduce the proportions of patients with hematologic ADRs during thiopurine treatment for IBD. However, there was a 10-fold reduction in hematologic ADRs among variant carriers who were identified and received a dose reduction, compared with variant carriers who did not, without differences in treatment efficacy. ClinicalTrials.gov number: NCT00521950.
|
Authors | Marieke J H Coenen, Dirk J de Jong, Corine J van Marrewijk, Luc J J Derijks, Sita H Vermeulen, Dennis R Wong, Olaf H Klungel, Andre L M Verbeek, Piet M Hooymans, Wilbert H M Peters, Rene H M te Morsche, William G Newman, Hans Scheffer, Henk-Jan Guchelaar, Barbara Franke, TOPIC Recruitment Team |
Journal | Gastroenterology
(Gastroenterology)
Vol. 149
Issue 4
Pg. 907-17.e7
(Oct 2015)
ISSN: 1528-0012 [Electronic] United States |
PMID | 26072396
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents
- Gastrointestinal Agents
- Mercaptopurine
- Methyltransferases
- thiopurine methyltransferase
- Azathioprine
|
Topics |
- Adult
- Anti-Inflammatory Agents
(administration & dosage, adverse effects, metabolism)
- Azathioprine
(administration & dosage, adverse effects, metabolism)
- Colitis, Ulcerative
(diagnosis, drug therapy, enzymology, genetics)
- Crohn Disease
(diagnosis, drug therapy, enzymology, genetics)
- Drug Dosage Calculations
- Female
- Gastrointestinal Agents
(administration & dosage, adverse effects, metabolism)
- Genetic Testing
- Genetic Variation
- Heterozygote
- Homozygote
- Humans
- Leukopenia
(chemically induced, prevention & control)
- Male
- Mercaptopurine
(administration & dosage, adverse effects, metabolism)
- Methyltransferases
(genetics, metabolism)
- Middle Aged
- Netherlands
- Pharmacogenetics
- Phenotype
- Predictive Value of Tests
- Prospective Studies
- Risk Factors
- Thrombocytopenia
(chemically induced, prevention & control)
- Treatment Outcome
- Young Adult
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|